FindMyKOL
Clinical trialNCT03397186WithdrawnPhase 2Interventional

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

NCT03397186 is a phase 2 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it was withdrawn. It studies Trabectedin in Metastatic Soft Tissue Sarcoma, Myxoid Liposarcoma and 4 more conditions. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 19 Jun 2018 and a primary completion date of 1 Jan 2021. One of its registered investigators has a FindMyKOL profile.

SponsorFred Hutchinson Cancer Center →Enrollment0Metastatic Soft Tissue SarcomaMyxoid LiposarcomaRound Cell LiposarcomaStage III Soft Tissue Sarcoma AJCC v7Stage IV Soft Tissue Sarcoma AJCC v7Unresectable Soft Tissue Sarcoma
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03397186
FieldValue
Registry IDNCT03397186
StatusWithdrawn
PhasePhase 2
Study typeInterventional trial
Lead sponsorFred Hutchinson Cancer Center
Enrollment0
Registered sites1
Countries1
ConditionsMetastatic Soft Tissue Sarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7 and Unresectable Soft Tissue Sarcoma
DrugsTrabectedin
Start19 Jun 2018
Primary completion1 Jan 2021
Study completion1 May 2021
Last update posted10 Sept 2019

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research trial studies the immune changes following trabectedin in patients with sarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Analyzing tumor tissue may help to understand the changes in immune cells in or around the tumor or if there is an increase in immune cells in the tumor after receiving trabectedin.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Washington, United States1 site
  • Fred Hutch/university of Washington Cancer Consortium

    Seattle

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashington: 1 siteWA1MontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03397186

Each answer restates registry values shown on this page.

What is NCT03397186?

NCT03397186 is a phase 2 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies Trabectedin in Metastatic Soft Tissue Sarcoma, Myxoid Liposarcoma and 4 more conditions.

Who leads NCT03397186?

The registry names Seth Pollack (principal investigator, Fred Hutch/University of Washington Cancer Consortium) as the overall official.

Where does NCT03397186 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03397186 study?

The registered drug and biological interventions are Trabectedin.

When did NCT03397186 end?

The registry lists a primary completion date of 1 Jan 2021 and a study completion date of 1 May 2021. The sponsor last updated the record on 10 Sept 2019.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.